Marsha Fanucci
CIK 1298814 · SVP, Chief Financial Officer · last filed 2026-03-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$552.2K
Companies
8
Total Filings
71
Lifetime Open-Market Net
-$9.70M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GENB | Director | — | $12.96 | — | $0 | 1 | 2026-03-02 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | Director | 16,000 | $0.00 | $6 | $0 | 11 | 2024-06-07 |
| ALNY | Director | 136 | $287.80 | $39.1K | -$8.45M | 18 | 2023-05-19 |
| Forma Therapeutics Holdings, Inc. (FMTX) Delisted | Director | 0 | $20.01 | $0 | $0 | 5 | 2022-10-14 |
| CYCN | Director | 848 | $3.55 | $3.0K | $0 | 6 | 2022-06-16 |
| IRWD | Director | 132,663 | $3.85 | $510.1K | -$243.9K | 9 | 2019-04-03 |
| MOMENTA PHARMACEUTICALS INC (MNTA) Delisted | Director | 14,500 | — | — | -$416.0K | 11 | 2016-06-27 |
| MILLENNIUM PHARMACEUTICALS INC (MLNM) Delisted | SVP, Chief Financial Officer | 5,217 | — | — | -$590.6K | 9 | 2008-05-15 |
Recent Filings · Page 2 of 8
71 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-06-02 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-20 | ALNY | Grant (A) | — | $0 | EDGAR |
| 2022-02-25 | ALNY | Grant (A) | — | $0 | EDGAR |
| 2021-07-19 | ALNY | Grant (A) | — | $0 | EDGAR |
| 2021-06-28 | CYCN | Grant (A) | — | $0 | EDGAR |
| 2021-06-21 | Forma Therapeutics Holdings, Inc. (FMTX) Delisted | Grant (A) | +2,750 | $0 | EDGAR |
| 2021-06-10 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-07-06 | ALNY | Grant (A) | — | $0 | EDGAR |
| 2020-06-24 | Forma Therapeutics Holdings, Inc. (FMTX) Delisted | Mixed | −15,362 | $0 | EDGAR |
| 2020-06-22 | Forma Therapeutics Holdings, Inc. (FMTX) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.